Studies have demonstrated that treatment of pharmacists in the management of heart failure leads to better clinical outcomes, which include the use of targeted medical treatment guidelines and re-hospitalizations. This effect was different among different studies. The aim of this study was to evaluate the rates of hospitalization for any reason, hospitalization due to heart failure as well as the change in indirect markers (left ventricular emission section, functioning according to NYHA, need for variables) in patients with heart failure with low emission section treated with scovitril VOLSARTHEN WHO HAVE BEEN OPTIMIZED IN A PHARMACY CLINIC. January 2018.
The results of the main outcome analysis showed that 70 patients with pre-hospital information and afterward experienced a decrease in hospitalization for any reason (45.7% 12 months before starting treatment with scovitril valsartan compared to 24.3% during the first year of optimal treatment ; p=0.004). It was also found that the hospitalization rate due to heart failure decreased from 24.3% to 8.6% (p=0.003). Analysis of secondary outcomes after 6 months, which included 104 patients, showed an improvement in the emission segment (26% vs. 34%; p
Source:
Davis L. et al. Annals of Pharmacotherapy ( 2021). https://doi.org/10.1177/10600280211036149
Note: This article has been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here
